Serum inflammatory markers in relation to prostate cancer severity and death

Danielle Crawley, Robert Williams, Hans Garmo, Lars Holmberg, Par Stattin, Hakan Malmstrom, Mats Lambe, Niklas Hammar, Goran Walldius, David Robinson, Ingmar Jungner, Mieke Van Hemelrijck

Research output: Contribution to journalMeeting abstractpeer-review


Background: Inflammation is a well-documented driver of cancer development and progression. However, little is known about its role in prostate carcinogenesis. Thus, we aimed to investigate the association of C-reactive protein (CRP), haptoglobin, albumin and white blood cells (WBC) with prostate cancer severity and progression.

Method: We selected 8471 men with newly diagnosed prostate cancer from the Swedish Apolipoprotein Mortality Risk (AMORIS) study who had exposure measurements taken approximately 14 years prior to diagnosis. We calculated multivariable odds ratio (OR) and 95% confidence interval (CI) for the associations between the inflammatory markers and prostate cancer severity using logistic regression, while Cox proportional hazard regression was used for the associations with overall and prostate cancer death.

Results: Serum CRP levels were positively associated with risk of high risk and metastatic prostate cancer, and high PSA levels (≥20 μg/L) (OR: 1.29; 95% CI: 1.06–1.56, 1.32; 1.05–1.65 and 1.51; 1.26–1.81 respectively). Similar positive associations were seen for haptoglobin with metastatic prostate cancer, high PSA level and possibly high grade prostate cancer (1.38; 1.10–1.74, 1.50; 1.17–1.93 and 1.25; 1.00–1.56 respectively). While albumin was positively associated with Gleason 4 + 3 tumour (1.38; 1.02–1.86), the associations with high risk prostate cancer and high PSA levels (≥20 μg/L) were inverse (0.71; 0.56–0.89 and 0.72; 0.59–0.90). However, none of these markers were associated with prostate cancer death or overall death. WBC was not associated with any of the outcomes.

Conclusion: Systemic inflammation as early as 14 years prior to diagnosis may influence prostate cancer severity, raising the question whether the host environment influences progression to a more malignant phenotype – or helps select more malignant cell-clones – early in the natural history of the disease.
Original languageEnglish
Pages (from-to)2223-2224
Number of pages2
JournalEuropean Journal of Surgical Oncology
Issue number11
Early online date22 Nov 2017
Publication statusPublished - Nov 2017


Dive into the research topics of 'Serum inflammatory markers in relation to prostate cancer severity and death'. Together they form a unique fingerprint.

Cite this